Navigation Links
CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
Date:5/16/2008

PHILADELPHIA, May 16, 2008 New data show that CAPHOSOL (www.caphosol.com), an advanced electrolyte solution, relieves painful oral mucositis (OM) and improves quality of life for cancer patients undergoing chemotherapy and radiation therapy. These data will be reported in two separate presentations, one today in an oral podium presentation and one tomorrow as a poster session, at the 33rd Annual Congress of the Oncology Nursing Society (ONS). These data confirm that CAPHOSOL is a useful tool to help oncology nurses and other healthcare professionals in the management of OM and related symptoms, particularly in patients with head and neck cancer and those receiving chemotherapy.

One of the two abstracts including this data, ONS Abstract #2757, "Supersaturated Electrolyte Oral Rinse Aids Quality of Life for Head/Neck Chemoradiation Patients" (Haas, ML), was selected by an ONS Expert Panel as one of the Top Ten Best Supportive Care abstracts at the ONS 2008 Congress.

Oral mucositis is a painful, common side effect experienced by cancer patients receiving chemotherapy and radiation therapy, commented principal investigator Marilyn L. Haas, PhD, RN, CNS, ANP-C, Nurse Practitioner, Mountain Radiation Oncology, Asheville, N.C. As layers of epithelial cells in the oral cavity (cells lining the surface of the throat and esophagus) are eroded during therapy, patients often experience severe pain, are more prone to infection and have difficulty eating and swallowing. Our research concludes that CAPHOSOL, a supersaturated electrolyte oral rinse, should be introduced early in the course of cancer therapy for patients at high risk of oral mucositis because it minimizes the onset and severity of symptoms.

The rate of severe oral mucositis (NCI Clinical OM Grade 3-4) reported by head and neck cancer patients using CAPHOSOL in this study was 11% (Grade 3) and 2% (Grade 4). Historically, the incidence of sever
'/>"/>

Contact: David Avitabile
davitabile@jfkhealth.com
609-514-5117
JFK Communcations
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. More than words: childbirth training change improves safety, cuts unnecessary procedures
2. New surgery improves head and neck cancer treatment
3. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
4. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
5. New clinical data shows chromium picolinate improves cognitive function
6. Teamwork improves learning and career success
7. Endobronchial valve significantly improves emphysema
8. Exercise improves thinking, reduces diabetes risk in overweight children
9. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians
10. Tooth loss strongly linked to risk of esophageal, head and neck, and lung cancer
11. Molecular clock could predict risk for developing breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... long wondered if local animal cultures exist, and now, ... Primate Research Center at Emory University, the University of ... answer: Yes. , The study, available in today’s ... the capacity to sustain the same kind of multiple-tradition ...
... be living with Alzheimer’s disease in 2006, according to a ... of Public Health. The researchers also concluded the global prevalence ... by 2050. By that time, 43 percent of those with ... a nursing home. The findings were presented June 10 at ...
... in Northern Ireland since the early 1990s and are more ... more affluent areas, according to a study just published in ... who looked at official cancer statistics for nearly 23,000 patients ... in patients and a 62 per cent increase in skin ...
Cached Biology News:New collaborative research reveals chimpanzees can sustain multiple-tradition cultures 2Alzheimer's disease to quadruple worldwide by 2050 2Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 2Rising skin cancer rates are more likely to affect wealthy people, says 12-year review 3
(Date:12/22/2014)... TENN (PRWEB) December 22, 2014 Fertility ... Donor Egg Bank USA , a network of ... country. Through this partnership, patients have fast access to ... in vitro fertilization, IVF . Fertility Associates of Memphis ... offer this fertility treatment option. , Dr. William ...
(Date:12/19/2014)... Dec. 19, 2014 Naurex Inc., a biopharmaceutical ... for diseases of the central nervous system, today announced ... executive officer, will present at the 33 rd ... take place at 3:00 p.m. PST on Tuesday, January ... San Francisco, Calif. ...
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/fhh9rj/technology ... "Technology Innovations in Smart Fabrics (Technical Insights)" ... http://photos.prnewswire.com/prnh/20130307/600769 The Research Service ... detailed assessment on technological advancements and market for ... 1. The Smart Fabrics market is expected ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for Research ... in the Neurosciences (CEN), and professor of pharmacology at ... a member of the prestigious Dana Alliance for Brain ... to receive this honor. , The Dana Alliance ... Dana Foundation. Its mission is to advance public ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Technology Innovations in Smart Fabrics (Technical Insights) 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... , , , ... (PTC) today announced the initiation of a Phase 2 clinical ... (NF2), a rare genetic disorder that causes the development of ... investigational new drug that is designed to selectively block tumor-related ...
... 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... of its contract manufacturer, SAFC Pharma(R), a Division of ... production run of REOLYSIN under cGMP conditions. This run ... to be completed over the next several years as ...
... , , CAMBRIDGE, Mass., ... and developing innovative treatments for pain, announced that David Julius, ... the University of California, San Francisco, and a leading pioneer ... board. , , "We admire Professor ...
Cached Biology Technology:PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 2PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 3PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 4Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R) 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3
Request Info...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Chicken polyclonal to ADI1 ( Abpromise for all tested applications). Antigen: Full length native protein (purified), corresponding to amino acids 1-179 of Human ADI1. Entrez GeneID: 55256 ...
Request Info...
Biology Products: